Centivax and US Naval Medical Research Center announce strategic partnership
Centivax has entered into a strategic partnership with the US Naval Medical Research Center to develop Centi-B9, a broad-spectrum injectable antibody therapeutic and prophylactic for COVID-19. The Phase I trial aims to demonstrate safety and pharmacokinetics of Centi-B9 in healthy volunteers.